As American Leadership is crucial in bringing the world out of the shadow of covid19. In advocating for American Values, defending human rights, transparency, and Economic Freedom and seeking to ensure a more secure, stable, and prosperous world, where democracy and freedoms are able to flourish, we are all working towards that end. With that in mind, i wish to again thank our nominees for appearing and your willingness to continuing our nation. Today, this committee will consider the nominations of six individuals to represent the United States of america. The nominees before us are mr. William, doug douglas, to serve as the u. S. Ambassador to the commonwealth of the bahamas. Higgins to be the u. S. To the republic of burgundy. Ms. Jean maloney to be the ambassador of the kingdom of s bikini. Mr. Michael mccarthy to serve as the u. S. Ambassador to the republic of liberia. Singh toable monisha be u. S. Representative to the organization for Economic Cooperation and development with t
Foreign Relations Committee hearing on the president s pick for several ambassadorial positions including james story to be u. S. Ambassador to venezuela, and William Douglas to be the u. S. Ambassador to the bahamas. Want to thank each of our nominees today for their willingness to serve in these important roles and to my colleagues on this committee for joining this hearing. One of this committees most important tasks i have discovered is to review and evaluate the president s nominee to serve in critical posts around the globe, like those you aim to serve. These nominees serve as the most window into america and to our universal values. ,he willingness of talented qualified individuals to serve has never been more valuable than it is today. As American Leadership is crucial in bringing the world out of the shadow of covid19. In advocating for American Values, defending human rights, transparency, and Economic Freedom and seeking to ensure a more secure, stable, and prosperous world,
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So